TickerSpark Feed

GH coverage

Every article, report, and earnings note where GH appears.

Interpace Biosciences Uplisting: Thyroid Testing Growth Meets a Tight Float
IPOIDXG

Interpace Biosciences Uplisting: Thyroid Testing Growth Meets a Tight Float

Interpace Biosciences, Inc. (NASDAQ: IDXG) is expected to list on 2026-10-21, with a $6.00-$7.00 price range and 3.1 million shares offered. The company is already public on OTC-style markets, so this is an uplisting and offering rather than a classic first-time IPO. Bull case: a profitable thyroid diagnostics niche with growing revenue; bear case: customer concentration and reimbursement risk still matter.

Oct 20, 20266 MIN
On-Demand Research

Want a deeper dive on GH?

Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.

Generate GH Report